Ruben M Rodriguez

US Patent:

20100264594, Oct 21, 2010

Filed:

Apr 14, 2010

Appl. No.:

12/760498

Inventors:

Andy Tsung - Pomona CA, US
Jesus Perea-Ochoa - Montebello CA, US
Ruben Rodriguez - Walnut CA, US

Assignee:

TRIPLE ACES CARD GAME INC. - Pomona CA

International Classification:

A63F 1/00

US Classification:

273292

Abstract:

A card game has three card hands in a round. A player compares three card hands for hand strength first categorizing hands into classes; wherein the highest special hand is the three of a kind. The second highest special class is the three face card hand. A standard hand class is below two special hand classes.

US Patent:

20120083324, Apr 5, 2012

Filed:

Sep 30, 2010

Appl. No.:

12/924651

Inventors:

Jesus Perea-OcHoa - Montebello CA, US
Ruben Rodriguez - Montebello CA, US

International Classification:

A63F 9/24

US Classification:

463 11, 463 42

Abstract:

A method playing games includes the steps of allowing a plurality of players to play the game via a plurality of individual electronic devices respectively; remotely linking the individual electronic devices to a networking system, wherein the players are able to play the game with each other through the networking system in a real time manner; and enabling the players to chat with each other through the networking system in a real time manner, wherein the players are able to remotely and simultaneously play the game and chart with each other via the individual electronic devices through the to networking system. Therefore, the networking system forms not only a playing channel for the player to play the game but also a communication channel for the players to chat so as to enhance the entertainment of the game, casino and safety.

US Patent:

20210040449, Feb 11, 2021

Filed:

Feb 15, 2019

Appl. No.:

16/969127

Inventors:

- Santa Monica CA, US
Rajul JAIN - Santa Monica CA, US
Yong OUYANG - Santa Monica CA, US
Arianne PEREZ GARCIA - Santa Monica CA, US
Margo ROBERTS - Santa Monica CA, US
Ruben ALVAREZ RODRIGUEZ - Santa Monica CA, US
Drake SMITH - Santa Monica CA, US
Xingliang ZHOU - Santa Monica CA, US

International Classification:

C12N 5/0783
C12N 15/10
C07K 14/725
C07K 14/74
C12N 5/074

Abstract:

The disclosure provides a method of generating modified T cells from engineered stem cells for use in an autologous or allogeneic setting for engineered immunotherapy. The knockout of endogenous TCR or HLA expression allows for engineering of modified pluripotent stem cells that reduce or eliminate the risk of Graft versus Host Disease (GVHD), provide resistance to elimination by a recipient's T cells and NK cells, and allow for controllable T cell activity. Thus, this method allows the development of T cells with reduced immune reactivity.

US Patent:

20200246382, Aug 6, 2020

Filed:

Dec 11, 2019

Appl. No.:

16/711180

Inventors:

- Santa Monica CA, US
Stuart A. Sievers - Van Nuys CA, US
Ruben Alvarez Rodriguez - Los Angeles CA, US
Jonathan Belk - Lebanon NH, US

International Classification:

A61K 35/17
C07K 16/28
A61P 35/00

Abstract:

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

US Patent:

20200109209, Apr 9, 2020

Filed:

Sep 12, 2019

Appl. No.:

16/569341

Inventors:

- Santa Monica CA, US
Ruben ALVAREZ RODRIGUEZ - Los Angeles CA, US
Jonathan BELK - Lebanon NJ, US

International Classification:

C07K 16/28
C07K 14/705
A61K 31/675
A61K 31/7076
A61K 45/06
A61K 31/7088
A61P 35/00
A61P 35/02

Abstract:

The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

US Patent:

20180369284, Dec 27, 2018

Filed:

May 25, 2018

Appl. No.:

15/989730

Inventors:

- Santa Monica CA, US
Ruben Rodriguez - Santa Monica CA, US
Yong Ouyang - Santa Monica CA, US

International Classification:

A61K 35/17
C12N 5/00
C12N 5/0735

Abstract:

The disclosure provides a method of generating non-clustered stem cells. Cluster disruption prior to mesoderm differentiation increases yield and efficiency in hEMP and T cell differentiation. Thus, this method allows the development of improved methods of hEMP and T cell differentiation.

US Patent:

20170283500, Oct 5, 2017

Filed:

Mar 31, 2017

Appl. No.:

15/476699

Inventors:

- Santa Monica CA, US
Ruben ALVAREZ RODRIGUEZ - Los Angeles CA, US

International Classification:

C07K 16/28
C07K 14/725
C12N 15/86
C07K 14/705

Abstract:

Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.

US Patent:

20170283504, Oct 5, 2017

Filed:

Mar 31, 2017

Appl. No.:

15/476309

Inventors:

- Santa Monica CA, US
Ruben ALVAREZ RODRIGUEZ - Los Angeles CA, US

International Classification:

C07K 16/28
A61K 31/7076
A61K 31/675
C07K 14/705
A61K 35/17

Abstract:

The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.